July 11 | Thu Jul 11, 2013 6:39am EDT
July 11 (Reuters) - Rockwell Medical Inc said a late-stage trial of its experimental iron deficiency drug met the main goal of improving patients' hemoglobin levels.
The study was the first of two planned late-stage trials, and tested the drug, SFP, in adult patients with chronic kidney disease.
0 comments:
Post a Comment